Previous Close | 1.7900 |
Open | 1.7500 |
Bid | 1.9100 x 3000 |
Ask | 1.9300 x 1400 |
Day's Range | 1.7400 - 1.9350 |
52 Week Range | 0.6700 - 3.5000 |
Volume | |
Avg. Volume | 1,090,521 |
Market Cap | 18.136M |
Beta (5Y Monthly) | -0.01 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.8850 |
Earnings Date | Mar 29, 2023 - Apr 03, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 24.50 |
Enrollment concludes earlier than anticipated; pivotal top-line data now expected mid-2023WARREN, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that the last patient has been enrolled in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Bellerophon to receive a license payment of $6 million, as well as royalties on net sales in Greater ChinaWARREN, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that it has entered into a license agreement for the development and commercialization of INOpulse® with Baylor BioSciences, a life sciences compa